Magnus Financial Group LLC Raises Stake in Immunome, Inc. (NASDAQ:IMNM)

Magnus Financial Group LLC boosted its holdings in Immunome, Inc. (NASDAQ:IMNM) by 107.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 53,536 shares of the company’s stock after buying an additional 27,777 shares during the period. Magnus Financial Group LLC owned approximately 0.09% of Immunome worth $569,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Immunome by 6.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock valued at $359,000 after acquiring an additional 1,520 shares in the last quarter. Lord Abbett & CO. LLC raised its position in Immunome by 4.1% in the third quarter. Lord Abbett & CO. LLC now owns 450,280 shares of the company’s stock valued at $6,583,000 after purchasing an additional 17,566 shares during the period. Barclays PLC lifted its stake in shares of Immunome by 125.9% during the third quarter. Barclays PLC now owns 105,886 shares of the company’s stock worth $1,547,000 after purchasing an additional 59,016 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Immunome by 13.6% during the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after purchasing an additional 144,557 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Immunome in the third quarter valued at about $363,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Stock Up 0.4 %

IMNM opened at $10.21 on Thursday. Immunome, Inc. has a 12-month low of $8.97 and a 12-month high of $30.96. The firm’s fifty day moving average price is $11.33 and its 200 day moving average price is $12.87.

Insider Transactions at Immunome

In other news, CTO Philip Tsai bought 21,000 shares of the firm’s stock in a transaction dated Thursday, November 21st. The stock was bought at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the transaction, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Robert Lechleider purchased 15,805 shares of the stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.48 per share, with a total value of $149,831.40. Following the completion of the acquisition, the insider now directly owns 15,805 shares in the company, valued at approximately $149,831.40. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 102,862 shares of company stock valued at $978,045. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on IMNM shares. Piper Sandler reduced their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Monday, January 13th. Finally, Stephens started coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.